Health Trials

Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

ConditionsHeart Valve DiseaseMitral Valve (MV) RegurgitationMitral Valve DiseaseMitral Valve StenosisAortic Valve DiseaseAortic Valve StenosisTricuspid Valve DiseaseTricuspid Valve RegurgitationAortic Valve RegurgitationPulmonary Valve DiseaseTranscatheter Valve ReplacementTranscatheter Aortic Valve Replacement (TAVR)Transcatheter Pulmonary Valve Replacement (TPVR)Transcatheter Edge-to-edge Repair
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.

Eligibility criteria

Qualifiers

At least 18 years old;

Be willing and able to provide informed consent to participate in the study;

Grade II or higher Aortic valve regurgitation: regurgitant jet width >3 mm, jet width / LVOT diameter ≥25%, jet cross-sectional area/LVOT cross-sectional area ≥5%, effective regurgitant orifice area (EROA) ≥0.1 cm², regurgitant volume per beat (R Vol)≥30 ml, or regurgitant fraction (RF) ≥30%.

Moderate or higher aortic valve stenosis: peak velocity ≥3.0 m/s, Mean gradient ≥20 mm Hg, aortic valve area ≤1.5 cm², Indexed aortic valve area ≤0.85 cm²/m², or velocity ratio ≤0.50.

Disqualifiers

Patients who are unwilling to accept registration and follow-up;

Patients who cannot cooperate with information collection and follow-up due to mental illness or other conditions;

Patients whose life expectancy is less than 12 months due to non-cardiac diseases (such as cancer, liver disease, kidney disease, or end-stage lung disease).

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

Army Medical Center of PLA

Collaborator

Huaxi Hospital

Collaborator

Fuwai Yunnan Cardiovascular Hospital

Collaborator

People's Hospital of Xinjiang Uygur Autonomous Region

Collaborator

Second Xiangya Hospital of Central South University

Collaborator

Xiangya Hospital of Central South University

Collaborator

The General Hospital of Northern Theater Command

Collaborator

Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator

Fujian Provincial Hospital

Collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator

The Affiliated Hospital of Qingdao University

Collaborator

Renmin Hospital of Wuhan University

Collaborator

The First Affiliated Hospital of Air Force Medicial University

Collaborator

Navy General Hospital, Beijing

Collaborator

Source ClinicalTrials.gov